

SAMPLE

ANTICOAGULATION STRATEGIES FOR ACS AND PCI CONFERENCE

DISCLOSURE OF COMMERCIAL RELATIONSHIPS

July 10, 2006

It is the policy of Drexel University College of Medicine to insure balance, independence, objectivity, and scientific rigor in all its sponsored educational programs. Speakers at continuing medical education activities are required to disclose to the audience their financial relationships with the manufacturer(s) of any commercial products, goods or services related to the subject matter of the program topic. Any conflicts of interest must be resolved prior to the presentation and announced to the audience. The intent of this disclosure is to allow participants to form their own judgments about the educational content of this activity and determine whether the speaker's commercial interests influenced the presentation. In addition, speakers are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentation.

Faculty/Planning Committee

ADRIENNE AGNEW, MD.	Speakers Bureau for Pfizer, OrthoMcNeil and Boston Scientific. Potential conflicts of interest have been resolved by supporting the presentation with the best available evidence from medical literature
ALAN ASSTRID, M.D	Has no commercial relationships to disclose
WILLIAM BERLINGER, M.D.	Stockholder with GlaxoSmithKline, Pfizer and AztraZeneca, Speakers Bureau for Wyeth Potential conflicts of interest have been resolved by refraining from making recommendations regarding products or services
HARRY OSTRER, M.D.	Principal Investigator on clinical trails for Abbott Labs and Bristol Myers. The speaker will refrain from making recommendations about products or services.
JANE POLLACK, M.D.	Has no commercial relationships to disclose
RHONDA KARP, D.O.	Has no commercial relationships to disclose
RALPH WARRINGTON, M.D.	Speakers Bureau for Schering-Plough. Potential conflicts of interest have been resolved by supporting the presentation with the best available evidence from medical literature
LARRY ZELLNER, M.D.	Consultant for Biogen, Boeringer Ingelham, and Kos Pharmaceuticals. Speakers' bureau for Forest Labs, Kos Pharmaceuticals and Carlene. Potential conflicts of interest have been resolved by supporting the presentation with the best available evidence from medical literature